|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122148 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-09 14:39:47 |
|
注册时间: Date of Registration: |
2026-04-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
心力衰竭中西医结合诊疗方案临床应用评价研究 ——注册登记研究 |
|
Public title: |
Assessment of clinical application for Integrated Chinese and Western Medicine diagnosis and treatment protocol in Heart Failure: A registry study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
心力衰竭中西医结合诊疗方案临床应用评价研究 |
|
Scientific title: |
Assessment of clinical application for Integrated Chinese and Western Medicine diagnosis and treatment protocol in Heart Failure |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘午阳 |
研究负责人: |
毛静远 |
|
Applicant: |
Liu Wuyang |
Study leader: |
Mao Jingyuan |
|
申请注册联系人电话: Applicant telephone: |
+86 150 2636 1792 |
研究负责人电话:
Study leader's |
+86 138 2049 8886 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1950263150@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
jymao@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
天津市西青区昌凌路88号 |
研究负责人通讯地址: |
天津市西青区昌凌路88号 |
|
Applicant address: |
No.88 Changling Road, Xiqing District, Tianjin |
Study leader's address: |
No.88 Changling Road, Xiqing District, Tianjin |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
天津中医药大学第一附属医院 |
||
|
Applicant's institution: |
First Teaching Hospital of Tianiin University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
天津中医药大学第一附属医院 |
||
|
Affiliation of the Leader: |
First Teaching Hospital of Tianiin University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
TYLL2025[K]字086 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
天津中医药大学第一附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
IRB of The First Teaching Hospital of Tianjin University of TCM |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-10-29 00:00:00 | ||
|
伦理委员会联系人: |
郑子琦 |
||
|
Contact Name of the ethic committee: |
Zheng Ziqi |
||
|
伦理委员会联系地址: |
天津市西青区昌凌路88号 |
||
|
Contact Address of the ethic committee: |
No.88 Changling Road, Xiqing District, Tianjin |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 22 2798 6258 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
yfyyxyjdj@163.com |
|
研究实施负责(组长)单位: |
天津中医药大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
First Teaching Hospital of Tianiin University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
天津市西青区昌凌路88号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.88 Changling Road, Xiqing District, Tianjin |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家中医药管理局 |
||||||||||||||||||||||
|
Source(s) of funding: |
State Administration of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究疾病: |
心力衰竭 |
||||||||||||||||||||||
|
Target disease: |
Heart Failure |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
明确心衰中西医结合诊疗方案在真实世界中应用情况、疗效和安全性 |
||||||||||||||||||||||
|
Objectives of Study: |
To clarify the application, efficacy and safety of integrated traditional Chinese and Western medicine diagnosis and treatment of heart failure in the real world. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
回顾性队列病例组: 1.年龄18以上,性别不限。 2.以心力衰竭为主要住院原因的患者,包括新发心衰或慢性心衰失代偿。 3.2010年1月~2025年9月期间住院。 前瞻性队列病例组: 1.年龄在18~79岁,性别不限; 2.符合心力衰竭诊断标准; 3.签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
Retrospective cohort case series: 1. Age 18 or older, regardless of gender. 2. Patients with heart failure as the main cause of hospitalization, including new heart failure or chronic heart failure decompensation. 3. Hospitalized from January 2010 to September 2025. Prospective cohort case series: 1. Aged between 18 and 79 years, regardless of gender; 2. Meet the diagnostic criteria for heart failure; 3. Have signed the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
回顾性队列病例组: 因资料不全不能满足本研究病例报告表基本要求的病例。 前瞻性队列病例组: 1.已处于生命垂危状态; 2.合并肝、肾等重要脏器严重功能衰竭,以及恶性肿瘤、急性脑梗死等疾病者;; 3.恶性心律失常或严重的心动过缓者; 4.在治疗期间需特殊处理而影响心衰的临床治疗者; 5.计划接受冠状动脉血运重建、心脏再同步化、心脏机械辅助装置和心脏移植者; 6.患有精神障碍疾病,依从性较差者; 7.根据研究者判断,患者不能完成本研究者; 8.正在参加其他临床研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Retrospective cohort case series: Due to incomplete data, the cases could not meet the basic requirements of the case report table in this study. Prospective cohort case series: 1. Already in a life-threatening condition; 2. With severe dysfunction of important organs such as the liver and kidneys, or diseases such as malignant tumors and acute cerebral infarction; 3. With malignant arrhythmias or severe bradycardia; 4. Requiring special handling during treatment that may affect the clinical management of heart failure; 5. Planning to undergo coronary artery revascularization, cardiac resynchronization, cardiac mechanical assist devices, or heart transplantation; 6. With mental disorders and poor compliance; 7. Judged by the investigator to be unable to complete this study; 8. Currently participating in other clinical studies. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-10 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
通过向毛教授发送一份正式请求,并附上方法论上合理的建议,将提供未识别的参与者数据和数据字典(电子邮件,jymao@126.com) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The deidentified participant data and data dictionary will be made available by sending a formal request with methodologically sound proposal to Prof. Mao (E-mail, jymao@126.com) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Collection and Management System |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |